CytRx reports favourable progress update for its pivotal Phase II clinical trial with tamibarotene as a third-line treatment for acute promyelocytic leukaemia.

CytRx Corp provided a favourable progress update for its ongoing Phase II STAR-1 registration clinical trial to evaluate the efficacy and safety of orally administered tamibarotene as a third-line treatment for acute promyelocytic leukaemia (APL). The primary endpoint of the open-label, non-randomised STAR-1 trial is to determine the rate of durable complete response for tamibarotene therapy when administered as a single agent to adult patients following treatment failure with all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO). A durable complete response is achieved when no leukaemia cells can be found in the bone marrow (morphologic leukaemia-free state or MLFS), the patient's …